Get the Stockscreener App
11.21
1.30%
0.10
Enanta Pharmaceuticals Inc stock is traded at $11.21, with a volume of 22,165.
It is up +1.30% in the last 24 hours and down -1.36% over the past month.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$11.11
Open:
$11.12
24h Volume:
22,165
Relative Volume:
0.15
Market Cap:
$235.41M
Revenue:
$73.62M
Net Income/Loss:
$-138.24M
P/E Ratio:
-1.7758
EPS:
-6.3125
Net Cash Flow:
$-99.19M
1W Performance:
-2.13%
1M Performance:
-1.36%
6M Performance:
-25.81%
1Y Performance:
+20.11%
1-Day Range:
$10.99
$11.40
1-Week Range:
$10.71
$11.68
52-Week Range:
$8.08
$17.80
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Name
Enanta Pharmaceuticals Inc
Sector
Industry
Phone
617 607 0800
Address
500 ARSENAL STREET, WATERTOWN, MA
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Jul-06-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Jun-01-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-24-20 | Initiated | Evercore ISI | Underperform |
| Aug-28-20 | Resumed | ROTH Capital | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-27-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Mar-17-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-22-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-26-19 | Downgrade | JP Morgan | Neutral → Underweight |
| May-24-19 | Initiated | Wolfe Research | Outperform |
| Apr-23-19 | Upgrade | Berenberg | Hold → Buy |
| Dec-13-18 | Initiated | Berenberg | Hold |
| Jun-06-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-21-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-11-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Apr-28-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | Barclays | Underweight |
| Oct-23-15 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-23-15 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
View All
Enanta Pharmaceuticals Inc Stock (ENTA) Latest News
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Assenagon Asset Management S.A. Trims Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
(ENTA) On The My Stocks Page - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest Up 14.7% in October - MarketBeat
The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable - Yahoo Finance
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress boosts stock outlook - Investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Where are the Opportunities in (ENTA) - Stock Traders Daily
Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline - Insider Monkey
Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares - Yahoo Finance
Millennium Management LLC's Strategic Acquisition of Enanta Phar - GuruFocus.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Position Lowered by AQR Capital Management LLC - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.00 - MarketBeat
Trend Tracker for (ENTA) - Stock Traders Daily
Enanta shares reiterates Buy rating on RSV drug results By Investing.com - Investing.com Canada
Primary Biliary Cholangitis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai - The Globe and Mail
HC Wainwright Reiterates Buy Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat
A Glimpse Into The Expert Outlook On Enanta Pharma Through 4 Analysts - Benzinga
JMP Securities Reiterates "Market Outperform" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat
Enanta stock holds market outperform rating despite Pfizer drug halt By Investing.com - Investing.com Canada
Sei Investments Co. Sells 15,230 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Will Enanta Pharma Breathe Easy? - RTTNews
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt? - Simply Wall St
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? - MSN
American Century Companies Inc. Boosts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta shares hold as Baird affirms target on new data By Investing.com - Investing.com Canada
Enanta’s Phase II Challenge Data Position A Second Potential RSV Therapy - Scrip
Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Reiterated by JMP Securities - MarketBeat
Rhumbline Advisers Increases Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta’s next RSV pill raises ‘high bar set by zelicapavir’ - The Pharma Letter
Enanta reports promising results for RSV drug EDP-323 - Investing.com
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study - Benzinga
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) - BioSpace
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Armistice Capital LLC - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Bank of New York Mellon Corp - Defense World
Enanta Pharmaceuticals Inc [ENTA] Chief Medical Officer makes an insider sale of 5,375 shares worth 91,805. - Knox Daily
Is Enanta Pharmaceuticals Inc (ENTA) a good investment opportunity? - US Post News
Gaining Ground: Enanta Pharmaceuticals Inc (ENTA) Closes Lower at 11.30, Down -0.79 - The Dwinnex
(ENTA) Investment Analysis - Stock Traders Daily
Envestnet (NYSE:ENV) Earns "Neutral" Rating from DA Davidson - MarketBeat
Rhumbline Advisers Raises Stock Holdings in Enovix Co. (NASDAQ:ENVX) - Defense World
Enel Chile (NYSE:ENIC) Trading Down 2.6% - MarketBeat
Smart Money Is Betting Big In ENVX Options - Benzinga
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Stock Traders Buy Large Volume of Put Options on Enovix (NASDAQ:ENVX) - MarketBeat
Enovix Co. (NASDAQ:ENVX) Shares Acquired by Oppenheimer & Co. Inc. - Defense World
Enel Chile S.A. (NYSE:ENIC) Short Interest Up 52.1% in August - Defense World
Principal Financial Group Inc. Increases Holdings in Enovix Co. (NASDAQ:ENVX) - Defense World
Rhumbline Advisers Sells 6,177 Shares of Enova International, Inc. (NYSE:ENVA) - Defense World
Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):